GÉNOMIQUE | THÉRAPIES CELLULAIRES & GÉNÉTIQUES | BIOPRODUCTION
See the original post here:
Génomique | Thérapies Cellulaires & Génétiques | Bioproduction - RÉSULTATS ANNUELS 2022
- Presentations to cover updated clinical and preclinical data on pipeline candidates in Company’s thyroid eye disease program -
Go here to read the rest:
UPDATE – Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology
VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (the “Company”) (TSXV:RKV) today announced the presentation of new data describing the progress of the Company’s kt-3000 drug development program at the American Association of Cancer Research (AACR) annual meeting in Orlando, Florida.
View original post here:
Rakovina Therapeutics Announces Presentation of New kt-3000 Series Data at AACR Annual Meeting
SHANGHAI, China, April 20, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced that positive interim event-free survival (EFS) results from the Neotorch study were presented at the ASCO April Plenary Series.
REDWOOD CITY, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter of 2023 after market close on Tuesday, May 9, 2023. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
See the article here:
Seer to Report First Quarter 2023 Financial Results on May 9, 2023
DUBLIN, Ireland, April 20, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to thirty two (32) new employees to purchase an aggregate of 236,000 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employee’s acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of the grant date and 25% on each anniversary thereafter. The options are subject to the terms and conditions of Avadel’s 2021 Inducement Plan approved by the Board of Directors in November 2021 and the terms and conditions of award agreements covering the grants.
Read more:
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
CUPERTINO, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting a poster at the 78th Annual Scientific Convention of the Society of Biological Psychiatry, to be held in San Diego, CA April 27-29, 2023.
Read more from the original source:
Reviva Pharmaceuticals to Present on Novel Serotonin-Dopamine Stabilizer Brilaroxazine at the 78th Annual Scientific Convention of the Society of...
FREMONT, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the first quarter 2023 after market close on Tuesday, May 9th, 2023. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.
Here is the original post:
Cytek Biosciences to Report First Quarter 2023 Financial Results on May 9, 2023
SOUTH SAN FRANCISCO, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the appointment of Timothy Moore to Executive Vice President, Chief Technical Officer effective April 24, 2023. The selection of Mr. Moore, the former Executive Vice President, Technical Operations of Kite Pharma responsible for the global development of two of the most commercially successful autologous CAR T manufacturing processes in the industry, reinforces the Company’s mission to being the first to bring an AlloCAR T product to market. Mr. Moore succeeds Alison Moore, Ph.D., who intends to serve as a consultant to Allogene.
Excerpt from:
Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer
Plus completes Phase 1/Part A of the ReSPECT-LM trial
Read more:
Plus Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights